The International Journal of Neuropsychopharmacology
September 9, 2026
B Richardson, S Socolow, Martha López-canul et al.
Abstract Background Recent clinical trials show that 5-MeO-DMT produces rapid antidepressant effects, yet the receptor mechanisms underlying these outcomes remain incompletely defined. Although 5-MeO-DMT is a high-affinity agonist at multiple serotonergic receptors, the relative contribution of 5-HT1A and 5-HT2A receptor signaling to its antidepressant-like actions has not been causally...
The International Journal of Neuropsychopharmacology
September 9, 2026
S Socolow, B Richardson, Sofia Nasini et al.
Abstract Background Major depression (MD) is a prevalent and debilitating disorder, characterized by anhedonia, persistent low mood, and learned helplessness, affecting up to 21% of adults over a lifetime. Chronic stress is a major environmental contributor to MD, and preclinical models of chronic mild stress (CMS) allow investigation of its behavioral and neurobiological consequences....
The International Journal of Neuropsychopharmacology
September 9, 2026
Romain Hacquet, P Pantiya, G Gotti et al.
Abstract Background Psychedelics such as psilocybin have demonstrated rapid and sustained antidepressant effects in humans, particularly when administered in carefully designed therapeutic environments (Borkel et al., 2024; Carhart-Harris et al., 2021). DMT and 5-MeO-DMT, distinguished by their brief duration of psychedelic effects, have also shown encouraging preliminary outcomes in depressive...
Brain Research
September 7, 2026
Eleni Kroupi, Helena Araujo, Cas Oosterveld et al.
N,N-Dimethyltryptamine (DMT), a potent serotonin-2A receptor agonist, elicits intense psychedelic experiences and has become a focus of interest in neuroscience and mental health research. While EEG studies of psychedelics typically report reduced alpha power, increased delta power, and enhanced signal complexity-primarily assessed using Lempel-Ziv complexity (LZc)-less is known about DMT's...
Journal of Psychoactive Drugs
September 7, 2026
Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała
This qualitative study examines self-reported experiences with 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) shared on Reddit to explore subjective reports, contextual influences, and perceived effects. A total of 120 posts from 24 discussion threads were purposively selected and thematically analyzed using an inductive, constructivist approach. The analysis resulted in 48 codes, which were...
Canadian Journal of Chemistry
September 4, 2026
Anton A. Homon, Pavithra Prasad, Jaxon Laramie et al.
The recent resurgence in psychedelic research has increased demand for these molecules for clinical studies. Due to the differences between national regulations and considering the dominance of the American market and its continued prohibition of many such molecules, the commercial availability of many of these compounds remains poor. This has also inhibited research into developing scalable...
Journal of Psychopharmacology
September 3, 2026
Katelijne V. van der Heijden, Gabriël E. Jacobs, Ellen James et al.
Serotonergic psychedelics, such as N,N-dimethyltryptamine (DMT), have shown therapeutic potential in various psychiatric disorders. However, DMT demonstrates pharmacokinetic (PK) variability and a short half-life. This exploratory study investigated the PK, pharmacodynamic (PD), and safety profile of CYB004, a deuterated DMT analogue, following intravenous administration in healthy volunteers....
Nutritional Psychiatry
September 1, 2026
Agnieszka Mechlińska, Aleksander Kwaśny, Michał Pastuszak et al.
ABSTRACT Psychedelic compounds exhibit diverse pharmacological and clinical effects, underscoring the need for further research and the development of clear guidelines to support their safe and effective clinical use. Growing interest in psychedelics has also increased attention toward the relationship between nutrition, dietary habits, and psychiatric disorders. This narrative review presents...
Journal of Psychopharmacology
August 31, 2026
Katelijne V. van der Heijden, Soma Makai‐bölöni, Amir Inamdar et al.
BACKGROUND: -dimethyltryptamine (DMT) might have therapeutic effects in various psychiatric disorders. AIMS: Prior to exploring this clinical potential, it is essential to determine an optimal administration regimen for DMT, explore the relationship between its pharmacokinetics (PK) and pharmacodynamics and identify potential sources of pharmacokinetic variability. METHODS: Therefore, DMT was...
August 28, 2026
Holly Hepburn
Renewed clinical interest in psychedelics has drawn attention to their challenging effects, yet most phenomenological and psychometric work derives from psilocybin, leaving cross-substance variation underexplored. This thesis employed codebook thematic analysis to examine challenging experiences across DMT, psilocybin, MDMA, and ketamine, utilising 146 naturalistic accounts collected from...